Clear impact

IN.PACT^TMAV Access Trial
5 years safety follow-up data
now released

IN.PACT^TMAdmiral^TM†DCB for AV Fistula:
the proactive approach for AV Fistula maintenance in
end-stage renal disease (ESRD) patients.

See study highlights

Alert Important Safety Information

Download presentation

Sustained impact

The IN.PACT™ AV Access Trial confirms the superiority of IN.PACT™ DCB (Drug-Coated Balloon) vs PTA through 3 years², showing safety profile through 5 years.³

Watch Dr. Holden present the IN.PACT™ AV Access Trial 5 year data at Charing Cross.

Proven impact

The first and only DCB trial in AVF to meet primary effectiveness and safety endpoints. See the manuscript published on the New England Journal of Medicine.

Read the manuscript

Fewer reinterventions than PTA¹ at 6 months.

78% highest reported access circuit primary patency1

Highest reported target lesion primary patency at 6 months¹.

86% highest reported target lesion primary patency1*

Highest reported target lesion primary patency at 6 months¹.

Now with proven data at 5-years. Watch the video to see the key results:

Hear from the experts

Watch Dr Mallios, Dr Holden, Prof Tozzi and Dr Steiner sharing insights on the latest data from the IN.PACT™ AV Access Trial. Discover the benefits of the IN.PACT™ DCB and its positive impact on AVF patients' quality of life.

Big impact

IN.PACT™ Admiral™^† for AV Fistula is a one-of-a-kind drug coated balloon that’s uniquely designed to address AV Access procedures needs:

Big diameters (up to 12mm) to increase treatment options
Short shaft to save procedure time

Find out more

Unique impact

Thanks to its unique drug-coated formulation, IN.PACT™ DCB (Drug-Coated Balloon) treats the causes of fistula stenosis, not just the symptoms. Combining an anti-proliferative drug and an excipient, it offers the highest reported primary patency of any DCB.^1*

Additional resources

IN.PACT™ Admiral™^†
Drug-Coated Balloon

Learn more

Contact Us

Request more information about IN.PACT^TM Admiral^TM Drug-Coated Balloon or any other product in our Peripheral portfolio.

*Indicates Required Field

Please select at least one option below:*

I would like to be contacted by a Medtronic representative

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

References

Lookstein RA, et al. Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas. N Engl J Med 2020;383:733-42. DOI: 10.1056/NEJMoa1914617. Highlighted results reported at both 180 and 210 days.

Holden A., IN.PACT AV Access Trial, 3-years results. Charing Cross London 2022.

Holden A. IN.PACT AV Access Outcomes: We know which DCB to use! Presented at Charing Cross 2024.

Footnotes

In an AV DCB study.

^†

The approved product name for the drug-coated balloon is IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter.